Wooree Bio우리바이오

Wooree Bio's trailing revenue is about ₩1.1T but it is loss-making at the operating line, and the share price has fallen sharply over the past year.

Wooree Bio runs five segments spanning health functional foods, FPCB and electronic components, LED packages, LED backlight units and TV assembly, and real estate leasing. For the twelve months to H1 2026 it reported revenue of ₩1.1T, an operating loss of about ₩4.2B and a net profit of ₩3.5B, with borrowings of ₩135B against cash of ₩128B. The shares closed at ₩4,260 on 2026-10-23, down 61.5% over one year.

What stands out

• Revenue fell 15.6% in 2025 to ₩1.04T, and trailing revenue to H1 2026 is ₩1.10T, so the top line has not yet recovered to 2024 levels of ₩1.24T.
• Operating income is negative on a trailing basis (about -0.4% margin), after a small profit in 2025 and a much larger one in 2021, while 2025 net income was a loss of ₩9.4B.
• The trailing net profit of ₩3.5B is positive but small, and free cash flow is negative at about -₩3.6B.
• Liabilities are 231.6% of equity and the company carries more borrowings than cash, a balance sheet that leaves little room for further losses.
• Foreign ownership dropped from 6% to 1.9% over about 60 days, and the data shows net foreign selling over the last 20 days.
• Filings in 2026 include a share consolidation decision, an extraordinary shareholders' meeting, a corporate value-up plan and two trading halts (August and September); the data does not explain the reasons for the halts.

What to watch

• The reason for the trading halts in August and September 2026 and any resulting disclosure, which the data does not describe.
• Effects of the 2026 share consolidation on the share count, which currently stands at about 9.7 million listed shares.
• Next quarterly or annual results, to see whether operating income turns and whether borrowings are reduced; no news headlines were included in the data.